Henry Schein, Inc. (HSIC) Shares Bought by Korea Investment CORP
Korea Investment CORP boosted its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 35.1% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 32,048 shares of the company’s stock after buying an additional 8,334 shares during the period. Korea Investment CORP’s holdings in Henry Schein were worth $5,865,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of HSIC. SpiderRock Advisors LLC purchased a new position in Henry Schein during the first quarter valued at $102,000. Lee Financial Co purchased a new position in Henry Schein during the second quarter valued at $161,000. Westside Investment Management Inc. purchased a new position in Henry Schein during the first quarter valued at $168,000. JNBA Financial Advisors purchased a new position in Henry Schein during the first quarter valued at $170,000. Finally, Peddock Capital Advisors LLC boosted its position in Henry Schein by 29.1% in the first quarter. Peddock Capital Advisors LLC now owns 1,097 shares of the company’s stock valued at $186,000 after buying an additional 247 shares during the last quarter. Hedge funds and other institutional investors own 90.87% of the company’s stock.
Shares of Henry Schein, Inc. (NASDAQ HSIC) opened at 170.58 on Friday. The firm has a market cap of $13.49 billion, a price-to-earnings ratio of 24.93 and a beta of 1.09. The company has a 50 day moving average of $181.54 and a 200 day moving average of $175.12. Henry Schein, Inc. has a 1-year low of $146.23 and a 1-year high of $186.99.
Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $1.75 EPS for the quarter, beating analysts’ consensus estimates of $1.73 by $0.02. The firm had revenue of $3.06 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Henry Schein had a net margin of 4.59% and a return on equity of 19.91%. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.64 earnings per share. On average, equities analysts forecast that Henry Schein, Inc. will post $7.28 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Henry Schein, Inc. (HSIC) Shares Bought by Korea Investment CORP” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://theolympiareport.com/2017/08/12/henry-schein-inc-hsic-shares-bought-by-korea-investment-corp.html.
Several research firms have weighed in on HSIC. Credit Suisse Group reiterated a “hold” rating and set a $160.00 price objective on shares of Henry Schein in a research report on Thursday, July 13th. Barrington Research lifted their price objective on shares of Henry Schein from $196.00 to $198.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 10th. Zacks Investment Research upgraded shares of Henry Schein from a “hold” rating to a “buy” rating and set a $204.00 price objective on the stock in a research report on Thursday, May 25th. Stifel Nicolaus lifted their price objective on shares of Henry Schein from $174.00 to $178.00 and gave the stock a “hold” rating in a research report on Wednesday, May 10th. Finally, Piper Jaffray Companies began coverage on shares of Henry Schein in a research report on Monday, June 12th. They set a “neutral” rating and a $200.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $185.56.
Henry Schein Company Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.